Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tularik
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
pathologic diagnosis of unresectable HCC
chemotherapy-naïve for HCC
Child-Pugh Class A or B liver disease
measurable disease (i.e., at least one lesion that is at least 20 mm in one dimension) on computerized tomography (CT) scan or magnetic resonance imaging (MRI) or at least one lesion that is at least 10 mm on spiral CT scan
Karnofsky Performance Status of ≥ 70%
life expectancy of ≥ 12 weeks
adequate hematologic function (i.e., absolute neutrophil count \[ANC\] of ≥ 1500 cells/mm3, platelet count of ≥ 80,000 cells/mm3, hemoglobin of ≥ 8.5 g/dL)
total bilirubin of ≤ 1.5 upper limit of normal (ULN)
aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 5 ULN
serum creatinine of ≤ 2 x ULN
You may not be if
severe, concurrent disease that would make the subject inappropriate for enrollment
Subjects who have received prior intravenous or intra-arterial chemotherapy, chemoembolization, intratumoral ethanol injection, cryosurgery, radiofrequency ablation, or embolization for their HCC. (note: prior surgical resection, immunotherapy, hormonal therapy, radiotherapy, and/or orthotopic liver transplantation are allowed)
history of other cancer within the past 5 years other than adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
New York Heart Association (NYHA) class III or IV heart disease or a left ventricular ejection fraction of \<50% or acute anginal symptoms
females who are pregnant or breast-feeding
received any investigational agent within 4 weeks of enrollment
history of central nervous system metastases or carcinomatous meningitis
